FDA Returns To MDUFA Table With High, Low Proposals
This article was originally published in The Gray Sheet
The priorities-gap between FDA and industry in MDUFA IV negotiations is narrowing. In May, the agency returned with counter-proposals that reduce user-fee increases compared to its prior plans, though there is still at least a $160m difference from the most recent proposal that is public from industry.
You may also be interested in...
A envisioned Office of Patient Affairs being would help the agency gain insight into patient understanding, and tolerance of risks and benefits of regulated products, the agency says.
Standard US FDA medical device user-fee rates will go down by about 10.3% for PMAs and 510(k)s for fiscal year 2017 beginning Oct. 1. User-fee rates are calculated based on statutory FDA revenue targets adjusted by inflation and "excess" fees collected in prior years.
As the US heads into a COVID-19 storm with grave concerns about the lack of face masks and respirators for health care workers, the FDA has further relaxed federal oversight for such products, giving more responsibility to employers